Antibodies

15 May 2014

Lilly’s Necitumumab Improves Overall Survival In Largest Ever Phase III Study In First-Line Treatment Of Stage IV Squamous Non-Small Cell Lung Cancer

15 May 2014

Merck Announces New Retrospective Analysis Shows Significant Clinical Benefit in Overall Survival for Metastatic Colorectal Cancer Patients with RAS Wild-Type Tumors Receiving Erbitux plus FOLFIRI

14 May 2014

Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab

14 May 2014

CJSC BIOCAD Announces AcellBia is First mAb Biosimilar Approved by the Ministry of Health of the Russian Federation

12 May 2014

AstraZeneca announces MedImmune’s mavrilimumab and sifalimumab both met primary endpoints in Phase IIb studies

10 May 2014

Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis

9 May 2014

Experimental antibody shows early promise for treatment of childhood tumor

8 May 2014

AstraZeneca initiates phase III immunotherapy study for MEDI4736 in patients with lung cancer

7 May 2014

Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse® Antibodies and ImmunoGen Technology to Develop Novel Antibody-Drug Conjugate for HER2-Negative Breast Cancer

6 May 2014

Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma

6 May 2014

MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014

6 May 2014

ABLYNX’S INHALED ANTI-RSV NANOBODY, ALX-0171, SUCCESSFULLY COMPLETES TWO FURTHER PHASE I CLINICAL STUDIES

5 May 2014

FDA Approves Ibalizumab Manufactured by WuXi PharmaTech for Treatment of Patients on Expanded Access

5 May 2014

Covagen Initiates Phase Ib/IIa Study of Bispecific anti-TNF/IL-17A FynomAb COVA322

2 May 2014

Avaxia Biologics Reports that Lead Product AVX-470 Achieves Objectives in Phase 1b Clinical Trial in Ulcerative Colitis

1 May 2014

Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer

1 May 2014

New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients

1 May 2014

Slowing of Brain Atrophy and Reductions in New Multiple Sclerosis Lesions Sustained at Three Years in Patients Treated with Genzyme’s Lemtrada

29 April 2014

GSK announces start of phase III programme for mepolizumab in patients with COPD

29 April 2014

Glenmark’s novel monoclonal antibody GBR 900 for treatment of chronic pain entering human trials

28 April 2014

Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies

28 April 2014

Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis

28 April 2014

SANDOZ ACHIEVES IMPORTANT MILESTONES ON PHASE III TRIALS FOR KEY BIOSIMILARS PROGRAMS

25 April 2014

Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies Discovered with Theraclone Technology

25 April 2014

Daiichi Sankyo Announces Discontinuation of Phase 3 Clinical Trial in Japan of Nimotuzumab (DE-766) in Lung Cancer

24 April 2014

Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica (NMO) and Refractory Generalized Myasthenia Gravis (MG)

24 April 2014

Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis

24 April 2014

Prothena’s NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain (AL) Amyloidosis

24 April 2014

FDA approves Sylvant for rare Castleman’s disease

23 April 2014

ABLYNX INITIATES PHASE I BIOAVAILABILITY STUDY WITH SUBCUTANEOUS FORMULATION OF ITS ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Report Package: Bispecific Antibodies

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

PD-1 Agonists Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

CD40 Agonists & CD40/L Antagonists Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review